% | $
Quotes you view appear here for quick access.

Insmed Incorporated Message Board

  • rehdvm2004 rehdvm2004 Jul 1, 2013 11:17 AM Flag

    Totally surprised, but this can happen when . . .

    The drug under trial is compared to a "positive control" (i.e., a control that has a similar drug effect. So when Cayston (Gilead) was compared to TOBI several years ago, several things were different. Cayston was a TID drug, which means the antibiotic effect could have been more penetrating and/or efficacious in terms of log kill. Most certainly Cayston did not have the lipid penetration and accumulation capability. So my first impression that Arikace should be compared with a negative control (liposome alone) was correct. Now there is more work ahead for INSM and the clinical trial team. Looks like NTM is going to be the "front burner" program. Sure hope that one gets two logs of kill of various NTM bacteria.

    Sentiment: Hold

    SortNewest  |  Oldest  |  Most Replied Expand all replies
13.76-0.24(-1.71%)Oct 27 4:00 PMEDT